Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthelabo covers the month of July 2002, specifically announcing the commencement of trading on the New York Stock Exchange (NYSE) on July 1, 2002. The company, formed in May 1999 via the merger of Sanofi and Synthelabo, is a leading global pharmaceutical firm. The filing details the listing of American Depositary Receipts (ADRs) under the ticker "SNY," representing one-half of an ordinary share, with the Bank of New York acting as depositary. No new shares were issued for this listing.
Key Financial Metrics
The filing provides historical financial data for the year 2001 under French GAAP. Specific figures for the six months ended June 30, 2002, are not included in this text.
- 2001 Consolidated Sales: EUR 6,488 million (15% increase over 2000).
- 2001 Developed Sales: EUR 8,746 million (21% increase over 2000). This metric includes sales from joint ventures with Bristol-Myers Squibb and Pharmacia.
- 2001 Net Profit: EUR 1,376 million before exceptional items and goodwill amortization (43% increase over 2000).
- 2001 U.S. Operations: Consolidated sales of EUR 1,083 million (28% increase); Developed sales of EUR 3,107 million (36% increase). U.S. operations contributed 36% of developed sales and 41% of operating profit.
- Debt and Liquidity: The filing text does not provide specific values for debt, cash flow, or liquidity ratios.
Material Changes and Product Performance
The company highlights significant growth driven by three blockbuster products and strategic expansions in the U.S. market.
- Plavix(R)/Iscover(R): 2001 consolidated sales reached EUR 705 million (62% increase); developed sales were EUR 2,033 million (55% increase).
- Ambien(R)/Stilnox(R): 2001 consolidated sales reached EUR 786 million (33% increase); developed sales were EUR 1,215 million (29% increase). Full marketing rights were secured via the acquisition of Pharmacia's stake in the Lorex joint venture in April 2002.
- Avapro(R)/Aprovel(R): 2001 consolidated sales reached EUR 423 million (42% increase); developed sales were EUR 924 million (37% increase).
- Elloxatine(R): 2001 sales reached EUR 196 million (41% increase). Granted FDA fast-track review status in April 2002 for metastatic colorectal cancer.
- Arixtra(R): Launched in the U.S. in Q1 2002 and in Europe in March 2002.
Guidance, Outlook, and Risks
Management views the NYSE listing as a natural move to increase visibility in the U.S. and broaden investor access. A targeted North American investor relations program is scheduled for September 2002, following the release of six-month results.
Regulatory Milestones (June 2002):
- Plavix(R): Received a positive opinion from the European CPMP for a new indication in Acute Coronary Syndrome (non-ST segment elevation).
- Aprovel(R)/Karvea(R): Approved by the European Commission for the treatment of diabetic renal disease in hypertensive type 2 diabetic patients.
- Elloxatine(R): Submitted the final component of the rolling New Drug Application (NDA) to the U.S. FDA for metastatic colorectal cancer.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks identified include the ability to expand U.S. presence profitably, the success of R&D programs, protection of intellectual property, and risks associated with healthcare reimbursement and pricing reforms in the U.S. and France.
Investor Verification Checklist
- Verify the specific financial results for the six months ended June 30, 2002, which are referenced but not detailed in this filing.
- Confirm the timeline for the European Commission's final approval of Plavix(R) following the positive CPMP opinion (typically four months).
- Monitor the FDA's decision on the NDA for Elloxatine(R) following the fast-track review status.
- Review the upcoming U.S. GAAP reconciliation, as the company currently reports under French GAAP.
- Assess the impact of the newly acquired full marketing rights for Ambien(R) on future U.S. revenue projections.